Fulminant myocarditis in adults and children: bi-ventricular assist device for recovery

Jean-Michel Grinda1, Patrick Chevalier, Nicola D'Attellis

  • 1Cardiac Surgery Department, Hôpital Europeen Georges Pompidou, 21 rue Leblanc 75908 Paris cedex 15, France. jean-michel.grinda@egp.ap-hop-paris.fr

Abstract

Insights

Fulminant myocarditis (FM) causing cardiogenic shock can be life-threatening. Mechanical paracorporeal biventricular assist devices (BiVADs) successfully bridged five patients to full recovery, offering a vital treatment option.

Area of Science:

  • Cardiology
  • Mechanical Circulatory Support
  • Myocardial Disease

Background:

  • Fulminant myocarditis (FM) can lead to severe, intractable cardiogenic shock.
  • Early intervention is critical to prevent multi-organ failure in FM patients.

Purpose of the Study:

  • To evaluate the efficacy of mechanical paracorporeal biventricular assist devices (BiVADs) as a bridge to recovery in patients with FM and cardiogenic shock.

Main Methods:

  • Five patients (four adults, one child) with FM underwent BiVAD implantation (MEDOS HIA-VAD) between 1999 and 2003.
  • Patients required maximal inotropic support, with some previously on intra-aortic balloon pump or ECMO.
  • Implantation was performed even in patients in cardiac arrest under external resuscitation.

Main Results:

  • All five patients were successfully bridged to recovery with BiVAD support, with no mortality.
  • Mean support duration was 11 days; four patients showed histological signs of FM.
  • At a mean follow-up of 31 months, all patients achieved full recovery with normalized LVEF (60%) and no ventricular dilatation.

Conclusions:

  • Mechanical paracorporeal BiVADs are a life-saving bridge to recovery for FM patients with intractable cardiogenic shock.
  • BiVAD support should be considered before the onset of multi-end organ failure.

Related Concept Videos

Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...